Navigation Links
A Settlement Has Been Proposed in a Class Action Lawsuit Involving Cold MD Dietary Supplement
Date:7/7/2009

LOS ANGELES, July 7 /PRNewswire/ -- A notice program authorized by the Los Angeles County Superior Court began over the weekend to alert those who purchased Cold MD dietary supplement from March 26, 2004 through May 29, 2009 about a proposed settlement against Iomedix Cold International SRL ("Defendant"). The notice is a result of the Court certifying, on May 29, 2009, a plaintiff class in a lawsuit alleging that Defendant made misleading or false statements about Cold MD dietary supplement.

The lawsuit, Eduardo Salcido, et al. v. Iomedix Cold International SRL, Case No. BC 387942, claims Defendant made false and misleading statements in their labeling and advertising of Cold MD dietary supplement. The settlement includes only the Cold MD dietary supplement, which was packaged as "Cold MD" and had the words, "Dietary Supplement" printed on the lower right corner of the box it was sold in. The Settlement does not mean that Defendant did anything wrong, and the Court has not decided that Defendant did anything wrong.

All Class Members can submit claims online at: www.ColdMDSettlement.com or via U.S. mail. Each Class Member who provides a valid receipt or credit card statement showing they purchased Cold MD dietary supplement will be sent a check in the amount of $10.00 for each bottle purchased during the Class Period. Each Class Member who does not have a valid receipt or credit card statement showing they purchased the Cold MD dietary supplement, but who submits the Declaration included in the Claim Form saying that they purchased the product, will be sent a check in the amount of $5.00 for each bottle purchased during the Class period (up to a maximum of three bottles if the Claim Form is submitted online at www.ColdMDSettlement.com and up to a maximum of six bottles if the Claim Form is sent via U.S. mail).

Notices informing Class members about their legal rights are appearing in national newspaper supplements and a consumer publication leading up to the hearing on October 20, 2009.

The Court appointed the law firm of Milstein, Adelman, & Kreger, LLP to represent the Class as Plaintiffs' Lead Class Counsel.

In addition to submitting a claim form to ask for payment, Class members can ask to be excluded from, or object to, the settlement. Claim forms must be postmarked no later than September 22, 2009. The deadline for exclusions and objections is August 24, 2009.

A toll-free number, 1-888-266-9438, has been established in this case along with a website, www.ColdMDSettlement.com, where notices, claim forms, the settlement agreement, and the Court's preliminary approval order may be obtained. Those affected also may write to: Cold MD Settlement Administrator, PO Box 3518, Portland, OR 97228-3518.


'/>"/>
SOURCE Cold MD Class Action Notice Administrator, Epiq Systems Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
2. MaxLife Fund Corp. purchases a portfolio of Life Settlement Policies with a face value of $4,000,000
3. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
4. $52.5 Million Settlement Against Sepracor Inc. Approved
5. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
6. Bristol-Myers Squibb Finalizes Settlement of Previously Disclosed Federal Investigation into Pricing, Sales and Marketing Practices
7. UGA study: Youth exposed to smokeless tobacco ads despite settlement
8. AARP Calls on State Regulators to Reject Proposed Settlement of TXU Buyout
9. AK Steel Reaches VEBA Health Care Settlement With Middletown Works Retirees
10. Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power
11. Mylan Announces Settlement of Paroxetine Hydrochloride Extended-Release Tablets with GlaxoSmithKline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... The Golseth Agency, a Texas based insurance ... is spearheading a regional charity campaign organized to provide support to Christina Upchurch and ... this year, Christina and her children returned from out of town to find her ...
(Date:8/18/2017)... Raton, Fl (PRWEB) , ... August 18, 2017 ... ... largest network of highly trained practitioners specializing in bioidentical hormone replacement therapy and ... associated with hormone imbalance and conditions of aging, such as menopause, andropause, thyroid ...
(Date:8/18/2017)... ... ... Alcovit, a lime-flavored beverage that rids the body of toxins linked to ... available through Jet.com. , After 25 years of development, the company released its ... quickly detox the body thereby avoiding alcohol-induced hangovers. Whether you’re having fun with friends ...
(Date:8/18/2017)... , ... August 18, 2017 , ... ... and call tracking and monitoring solutions, announced today the launch of a redesigned ... a modern navigation and aesthetic, fully responsive design, and an enhanced search directory ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Dangerous Inheritance”: a mystery about saving the family ... is from Southwest Nebraska where she was raised on a farm. As Diane ... is fictional, but the friendships and mantra of ‘neighbors helping neighbors’ have always been ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... , Aug. 15, 2017  Axium Pharmaceuticals Inc., the creator of ... to be in the beginning stages of an IPO. ... epilepsy medications with the average cost of a prescription epilepsy drug being ... AXIUM ... Another staggering figure is the fact that ...
(Date:8/14/2017)... TIKVAH, Israel , Aug. 15, 2017 ... developer of adult stem cell technologies for neurodegenerative diseases, ... 30, 2017. "We ... pivotal Phase 3 trial to investigate NurOwn ® ... Chief Executive Officer of BrainStorm. "We have agreements with ...
(Date:8/8/2017)... 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... its financial results for the second quarter ended June ... second quarter 2017 and to date: ... programs for the Company,s lead project, BL-8040: ... with BL-8040 as novel stem cell mobilization treatment for ...
Breaking Medicine Technology: